$PVLA News

Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally

Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy

FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations

Palvella Therapeutics Announces FDA Rolling Review Of Its New Drug Application For Qtorin Rapamycin For The Treatment Of Microcystic Lymphatic Malformations

Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum

Palvella Therapeutics, Inc. (PVLA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

Palvella Therapeutics Completes Pre-NDA Meeting With FDA For QTORIN 3.9% Rapamycin Anhydrous Gel In Microcystic Lymphatic Malformations; On Track To Submit NDA In H2 Of 2026

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

Palvella Therapeutics Receives U.S. Patent For Its Licensed QTORIN Pitavastatin Program For Porokeratosis

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards

Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations

Palvella Therapeutics Presents New Clinical Data From Phase 3 SELVA And Phase 2 TOIVA Studies At ISSVA World Congress 2026

Palvella’s QTORIN Trial Data Reframes Venous Malformation Outlook And Valuation

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

Palvella Therapeutics Presents New Data From Phase 2 TOIVA Trial Of QTORIN Rapamycin In Patients With Cutaneous Venous Malformations At Annual Meeting Of SID